Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (262)
  2. Journal Article (245)
  3. Review (26)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (573)
  2. Gastrointestinal Oncology Service (573)
  3. Solid Tumor Oncology Division (573)
  4. Center for Pancreatic Cancer Research (215)
  5. Epidemiology and Biostatistics (122)
  6. Surgery (103)

More Groups

People
  1. Eileen O'Reilly (156)
  2. James Harding (130)
  3. William Jarnagin (66)
  4. Marinela Capanu (65)
  5. Leonard Saltz (55)
  6. Imane El Dika (54)

More People

Years
  1. 2025 (18)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (166)
  2. Annals of Oncology (53)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (182)
  2. Oxford University Press (65)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (573)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: Phase 3 CALGB 80802 randomized clinical trial
    Journal Article

    Abou-Alfa, G. K.; Shi, Q.; Knox, J. J.; Kaubisch, A.; Niedzwiecki, D.; Posey, J.; Tan, B. R. Jr; Kavan, P.; Goel, R.; Lammers, P. E.; more...
    JAMA Oncology (2019)

    Fulltext@MSK | Save
  • Romiplostim treatment of chemotherapy-induced thrombocytopenia
    Journal Article

    Soff, G. A.; Miao, Y.; Bendheim, G.; Batista, J.; Mones, J. V.; Parameswaran, R.; Wilkins, C. R.; Devlin, S. M.; Abou-Alfa, G. K.; Cercek, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations
    Meeting Abstract

    Varghese, A. M.; Patel, J. A. A.; Janjigian, Y. Y.; Meng, F.; Selcuklu, S. D.; Zimel, C.; Hyman, D. M.; Iyer, G.; Houck-Loomis, B.; Abou-Alfa, G. K.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Park, W.; Wong, W.; Yu, K. H.; Varghese, A. M.; Riaz, N.; Balachandran, V. P.; El Dika, I. H.; Raj, N. P.; Khalil, D.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
    Meeting Abstract

    Javle, M. M.; Borbath, I.; Clarke, S. J.; Hitre, E.; Louvet, C.; Mercade, T. M.; Oh, D. Y.; Spratlin, J. L.; Valle, J. W.; Weiss, K. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial
    Meeting Abstract

    Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; Cicin, I.; Bolondi, L.; Klümpen, H. J.; Chan, S. L.; Dadduzio, V.; Milwee, S.; Dubey, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Halo 110-101: Early safety results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC)
    Meeting Abstract

    Oh, D. Y.; Muhsin, M.; Bullock, A. J.; Abou-Alfa, G. K.; Shroff, R. T.; Sigal, D.; Chung, V.; Hecht, J. R.; Wu, W.; Borad, M. J.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including hepatocellular carcinoma (HCC)
    Meeting Abstract

    Nguyen, L. T.; Chapel, S.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Abou-Alfa, G. K.; Lacy, S.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Kelley, R. K.; Rimassa, L.; Ryoo, B. Y.; Park, J. W.; Blanc, J. F.; Chan, S. L.; Dadduzio, V.; Yau, T. C.; Sen, S.; Markby, D. W.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II study of ADI-PEG 20 and FOLFOX6 in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Qin, S.; Yang, T. S.; Yen, C. J.; Chao, Y.; Wang, T. E.; Do, R. K. G.; El Dika, I. H.; Uhlitskykh, K.; Millang, B. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save